Acumen Pharmaceuticals, Inc.

02/11/2026

Today, on International Day of Women and Girls in Science, we celebrate the women and girls whose ideas, leadership, and resilience continue to push science forward.

At Acumen, we’re honored to work alongside women across our organization and extended scientific community who are advancing innovation and helping shape the future of Alzheimer’s research. Their impact reaches far beyond today and we’re proud to support it.

02/09/2026

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do!

February's 'Ask Acumen' featured team member is Kathy Marcozzi Pierce, Director, Clinical Operations.

🔗Click the link below to get a behind-the-scenes look at Kathy's journey, passions, and outstanding contributions to our mission: https://acumenpharm.com/ask-acumen/

02/04/2026

Today at the Alzheimer’s & Parkinson’s Drug Development Summit, Acumen CMO Eric Siemers MD presented on advancing disease‑modifying therapies through biomarker‑driven antibody innovation.

His session highlighted sabirnetug (ACU193), Acumen’s investigational next‑generation anti‑amyloid‑β oligomer antibody, designed to selectively target toxic Aβ oligomers. He also shared translational biomarker findings from the INTERCEPT‑AD Phase 1 trial and discussed how the ongoing ALTITUDE‑AD Phase 2 study is designed to confirm mechanistic action and evaluate clinical efficacy in early Alzheimer’s disease, with the goal of delivering meaningful outcomes for patients.

02/04/2026

We were proud to see Acumen represented on the keynote stage at the WCBP in Washington D.C. last week.

Our Senior Director of CMC Regulatory, Kathy Lee, joined industry leaders from Amgen and Danforth Health for a Keynote session on “The Heart of Innovation: Patients Shaping the Future of Biologics”.

The session highlighted how patient perspectives inform innovation across the biopharmaceutical lifecycle and why patient-centered approaches are essential to advancing access, quality, and impact.


CASSS - Sharing Science Solutions

01/26/2026

Having strong company values is vital to building a positive work culture and driving Acumen's mission forward. We want to share our values with the world in the hope that they may inspire others to join us in making a meaningful impact.

At Acumen, our top priority is people. We believe that people are the heart and soul of our company, and we are committed to making a difference in the lives of those impacted by Alzheimer's disease.

By putting people first, we ensure that our research and development efforts are geared towards creating targeted treatments that improve the quality of life for patients as well as their families and caregivers.

01/20/2026

We’re pleased to share a new Clinical Leader feature highlighting how Acumen is using a “study within a study” approach to better understand what works in Alzheimer’s trial recruitment.

Our CMO, Eric Siemers MD, and Associate Director of Communications Robyn Moxon sat down with Abby Proch to discuss how taking a closer look at our own strategies can help improve efficiency, reduce burden, and inform future trial design across the field.

Read the full conversation here: https://www.clinicalleader.com/doc/study-within-a-study-reveals-best-recruitment-strategies-for-alzheimer-s-trials-0001

In this Q&A, Acumen Pharmaceuticals shares findings from its Alzheimers recruitment study, highlighting what efforts proved the most fruitful.

01/13/2026

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do!

January's 'Ask Acumen' featured team member is Elizabeth Johnson, PhD, Senior Scientist, Discovery.

🔗Click the link below to get a behind-the-scenes look at Elizabeth's journey, passions, and outstanding contributions to our mission: https://acumenpharm.com/ask-acumen/

12/31/2025

Happy New Year from the Acumen Team - wishing you a healthy and hopeful 2026!

12/22/2025

This season, we're grateful for the moments of connection that move us forward, and for the patients, families, and partners who inspire our work every day.

Wishing you peace and joy during the holidays, and a hopeful start to the year ahead.

12/12/2025

Last week in San Diego, the Acumen team attended the CTAD Conference where we presented posters detailing a nonclinical Enhanced Brain Delivery (EBD™) study focusing on fusing transferrin receptor binders to sabirnetug to facilitate its transport through the blood-brain barrier as well as recruitment strategies for our Phase 2 ALTITUDE-AD study of sabirnetug.

To see our posters visit: https://acumenpharm.com/publications/

12/10/2025

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do!

December’s 'Ask Acumen' featured team member is Paul Shughrue, PhD, Research and Portfolio Lead.

🔗Click the link below to get a behind-the-scenes look at Paul’s journey, passions, and outstanding contributions to our mission: https://acumenpharm.com/ask-acumen/

12/05/2025

All good things must come to an end, and while the Acumen team is sad to leave hashtag , it’s been a wonderful week of sharing knowledge and innovation in the ’s field. We’ll see you all next year!